TargetBeta
ACVR1
activin A receptor type 1 · also SKR1, ALK2, ACVR1A, ACVRLK2 · Type 1 receptor serine/threonine kinases
2 programs in company-led studies act on ACVR1, from 2 companies: 2 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| momelotinibrule | GlaxoSmithKline | phase 3 | 174 running | JAK1, JAK2 | NCIt |
| pacritinibrule | Swedish Orphan Biovitrum | phase 3 | 183 running | FLT3, IRAK1, JAK2 | ChEMBL |
Conditions their studies are in
- Primary Myelofibrosis, 2 programs
- Carcinoma, Non-Small-Cell Lung, 1 program
- COVID-19, 1 program
- Hematologic Neoplasms, 1 program
- Hodgkin Disease, 1 program
- Leukemia, Myelomonocytic, Chronic, 1 program
- Myelodysplastic Syndromes, 1 program
- Polycythemia Vera, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 11, 2026momelotinib · GlaxoSmithKline · phase 3 · NCT03441113
- Dec 30, 2026pacritinib · Swedish Orphan Biovitrum · phase 3 · NCT06782373
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.